Description
Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.
Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.
This report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:
The Market for Liquid Biopsy by Region
- North America
- Europe
- Asia
- Rest of World
The Market for CTC-based Liquid Biopsy
The Market for ctDNA-based Liquid Biopsy
The Market for EV and Exosome-based Liquid Biopsy
The Market for Multi-Analyte-based Liquid Biopsy
The Market for Other Analytes Liquid Biopsy
Liquid Biopsy Market by Type of Cancer
- Breast
- Lung
- Colorectal
- Ovarian
- Prostate
- Pan-Cancer
- Other Cancer
R&D: Selected ctDNA-based Liquid Biopsy Tests in Development
On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:
- Early detection and diagnosis / screening
- Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
- Therapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
- Disease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
These applications, increasing acceptance, the use of liquid biopsy in combination with other technologies. This report contains market assessments for these application categories.
In addition, the report profiles key companies in the market, including:
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- Angle, PLC
- Aspira Women’s Health
- Biocartis Group Nv
- Biocept, Inc.
- Biodesix
- Cellmax Life
- Circulogene
- Diacarta, Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- Gilupi Gmbh
- Grail (Illumina)
- Guardant Health, Inc.
- Hologic
- Lunglife AI (Formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, SPA
- Myriad Genetics, Inc.
- Natera, Inc.
- Neogenomics Laboratories, Inc.
- Oncocyte Corporation
- Oncodna S.A.
- Personal Genome Diagnostics
- Qiagen N.V.
- Cell-Free DNA Technologies
- Ctc Technologies
- Exosome And Mirna Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- Volitionrx
Table of Contents
Chapter One: Executive Summary
Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Market for Liquid Biopsy 2022-2027
- Figure 1-2: Global Liquid Biopsy Market by Geographic Region, 2022 (%)
- Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2022-2027 $(M)
Chapter Two: Liquid Biopsy Technologies
Introduction
- Table 2-1: Comparison of Tissue and Liquid Biopsy
Current Major Liquid Biopsy Technologies
- Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
Current ctDNA-based Liquid Biopsy Tests
- Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2022Company/ Country
Biocartis
Biocept
Biodesix
CellMax Life
Circulogene
Diacarta
Epigenomics
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics
QIAGEN
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics
Tempus
ctDNA-based Liquid Biopsy Tests in Development
- Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2022
Exact Sciences
Freenome
GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
Introduction
Challenges in the Development of CTC-based Liquid Biopsy Tests
CTC-based Liquid Biopsy Tests
- Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2022
Adaptive Biotechnologies
ANGLE
Biocept
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
Selected CTC-based Liquid Biopsy Tests in Development
- Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2022
Epic Sciences
Liquid Biotech USA
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Introduction
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2022
Aspira Women’s Health (formerly Vermillion)
Biodesix
Exosome Diagnostics
Hologic
MDxHealth
Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2022
Circulogene
OncoCyte
Resolution Biosciences
VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
Introduction
Liquid Biopsy Tests Based on Multiple Analytes
- Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2022
Biocept
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA
Multiple Analyte-based Liquid Biopsy Tests in Development
- Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2022
Exact Sciences
Freenome
GRAIL
LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
Introduction
Liquid Biopsy Tests for Research Use Only
- Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2022
Agena Bioscience
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
Introduction
Tiers of Competition
- Table 8-1: Selected Participants in the Liquid Biopsy Market, 2022
Competitive Factors
Significant Market Trends
- Table 8-2: Significant Trends in the Liquid Biopsy Market, 2022
Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market
- Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
- Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
- Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
Market Forecast
- Table 9-2: Global Liquid Biopsy Market Forecast by Region – North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2022-2027
Chapter Ten: Market by Analyte
Circulating Tumor DNA
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2022-2027
Circulating Tumor Cells
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2022-2027
Extracellular Vesicles and Other Analytes
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2022-2027
Multiple Analytes
Market Overview
Revenue Forecast
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2022-2027
Chapter Eleven: Market by Application
Therapy Guidance and Monitoring
Market Overview
Revenue Forecast
- Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2022-2027
Diagnosis/Screening
Market Overview
Revenue Forecast
- Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2022-2027
Disease Prognosis
Market Overview
Revenue Forecast
- Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2022-2027
Chapter Twelve: Market by Cancer Type
Breast Cancer
Market Overview
Revenue Forecast
- Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2022-2027
Colorectal Cancer
Market Overview
Revenue Forecast
- Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2022-2027
Lung Cancer
Market Overview
Revenue Forecast
- Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2022-2027
Ovarian Cancer
Market Overview
Revenue Forecast
- Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2022-2027
Prostate Cancer
Market Overview
Revenue Forecast
- Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2022-2027
Other Cancers
Market Overview
Revenue Forecast
- Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2022-2027
Pan-Cancer Tests
Market Overview
Revenue Forecast
- Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2022-2027
Chapter Thirteen: Company Profiles
Companies in the Market
- Table 13-1 Companies in the Liquid Biopsy Market
Adaptive Biotechnologies
Agena Bioscience, Inc.
ANGLE, plc
Aspira Women’s Health
Biocartis Group NV
Biocept, Inc.
Biodesix
CellMax Life
Circulogene
DiaCarta, Inc.
Epic Sciences
Epigenomics AG
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc. (Roche)
Freenome, Inc.
GILUPI GmbH
GRAIL (Illumina)
Guardant Health, Inc.
Hologic
LungLife AI (formerly Cynvenio Biosystems)
Menarini-Silicon Biosystems, Spa
Myriad Genetics, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Oncocyte Corporation
OncoDNA S.A.
Personal Genome Diagnostics
QIAGEN N.V.
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
Resolution Biosciences (Agilent)
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus
VolitionRx
